Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Apogee Therapeutics, Inc. - Common Stock
(NQ:
APGE
)
48.36
+0.54 (+1.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Apogee Therapeutics, Inc. - Common Stock
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 19, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 12, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
May 28, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
May 15, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
May 06, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
March 25, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
March 12, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
March 07, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
March 04, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
IPO watch 2024: Which new stocks will hit the market?
January 08, 2024
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies.
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
October 30, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
September 27, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
September 14, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
August 28, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
August 21, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 07, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
August 02, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 18, 2023
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.